Share

October 25, 2016; 87 (17) Editorial

More data on the safety of generic substitution

Yes, the blue tablet is OK?

Gregory L. Krauss, Michael Privitera
First published September 28, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003272
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
120

Share

Article Information

vol. 87 no. 17 1754-1755
DOI: 
https://doi.org/10.1212/WNL.0000000000003272
PubMed: 
27683849
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published September 28, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Gregory L. Krauss, MD and
    2. Michael Privitera
  1. Gregory L. Krauss, MD and
    2. Scientific Advisory Boards:

    1. (1) Lundbeck Sabril safety board. 2) NINDS study safety board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Epilepsia, editorial board

    Patents:

    1. 1) provisional patent application for epilepsy seizure detector medical device

    Publishing Royalties:

    1. (1) The Johns Hopkins Digital EEG Atlas, JHU Press, 2006, 2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Eisai Inc, commercial entity 2) Acorda Inc, commercial entity.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) UCB Pharma, Principal Investigator, 2009-Present; (2) SK Life Science, Principal Investigator, 2012-Present; (3) Novartis, Principal Investigator, 2012-2015; 4) Pfizer, Principal investigator, 2015-Present.

    Research Support, Government Entities:

    1. (1) NIA, RC2AG036419, Principal Investigator, 2009-Present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Epilepsy Research Foundation, Co-Principal Investigator, 2009-Present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Abbott, medical legal review; 2016.

  2. Michael Privitera
    3. Scientific Advisory Boards:

    1. DSMB for Upsher Smith, Astellas, and consulting for Lilly

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board for Seizure

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. grant support from 1. UCB, Brivaracetam trial 2. Eisai, clinical trial of parampanel 3. Neuren pharmaceuticals, EEG interpretation for multicenter trial of traumatic brain injury 4. GW Pharmaceuticals, Epidiolex trial

    Research Support, Government Entities:

    1. 1) NIH, MONEAD trial, site PI NIH 2U01NS038455-11A1 2) FDA through SBIR FEFA awarded for EQUIGEN generic equivalence studies

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Shor Foundation for Epilepsy Research, studies on stress and seizures (no grant number) Epilepsy Foundation, EQUIGEN studies (no grant number) American Epilepsy Society, EQUIGEN studies (no grant number)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (G.L.K.), Johns Hopkins University, Baltimore, MD; and Department of Neurology (M.P.), University of Cincinnati Medical Center, Cincinnati, OH.
  1. Correspondence to Dr. Krauss: gkrauss{at}jhmi.edu
View Full Text

Article usage

Article usage: September 2016 to April 2023

AbstractFullPdfSource
Sep 20163302Highwire
Oct 201611783349Highwire
Nov 2016405816Highwire
Dec 20166546Highwire
Jan 20174323Highwire
Feb 20172711Highwire
Mar 20171723Highwire
Apr 20173120Highwire
May 20171521Highwire
Jun 20171413Highwire
Jul 20172711Highwire
Aug 20172300Highwire
Sep 20171501Highwire
Oct 20171634Highwire
Nov 20172312Highwire
Dec 2017900Highwire
Jan 20181311Highwire
Feb 2018711Highwire
Mar 20181311Highwire
Apr 20181510Highwire
May 2018802Highwire
Jun 2018901Highwire
Jul 20181000Highwire
Aug 20181211Highwire
Sep 20183421Highwire
Oct 20181022Highwire
Nov 20181911Highwire
Dec 20181501Highwire
Jan 20192010Highwire
Feb 2019600Highwire
Mar 20191700Highwire
Apr 2019410Highwire
May 20191620Highwire
Jun 2019700Highwire
Jul 2019211Highwire
Aug 2019223Highwire
Sep 2019810Highwire
Oct 20191311Highwire
Nov 20192100Highwire
Dec 2019611Highwire
Jan 2020600Highwire
Feb 2020800Highwire
Mar 2020710Highwire
Apr 2020200Highwire
May 2020301Highwire
Jun 20201002Highwire
Jul 2020300Highwire
Aug 2020500Highwire
Sep 20201110Highwire
Oct 20201400Highwire
Nov 20201510Highwire
Dec 2020800Highwire
Jan 2021900Highwire
Feb 2021720Highwire
Mar 20212100Highwire
Apr 2021500Highwire
May 2021900Highwire
Jun 20211100Highwire
Jul 20211110Highwire
Aug 20211200Highwire
Sep 2021500Highwire
Oct 20211711Highwire
Nov 20211100Highwire
Dec 20211700Highwire
Jan 2022900Highwire
Feb 20222003Highwire
Mar 20221000Highwire
Apr 2022600Highwire
May 2022800Highwire
Jun 20221600Highwire
Jul 20221001Highwire
Aug 20221000Highwire
Sep 2022900Highwire
Oct 20221000Highwire
Nov 2022800Highwire
Dec 2022700Highwire
Jan 2023632Highwire
Feb 2023600Highwire
Mar 2023700Highwire
Apr 2023400Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles